<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35044877</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy.</ArticleTitle><Pagination><StartPage>2024063</StartPage><MedlinePgn>2024063</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2024063</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.2024063</ELocationID><Abstract><AbstractText>In recent years, the Global Polio Eradication Initiative has gradually implemented a global shift in polio immunization programs. Few studies cover polio immunization program impacts on the efficacy of other vaccines. This study investigated whether polio immunization programs affected hepatitis A (HepA) and hepatitis B (HepB) vaccination efficacy. Serum samples were collected from 968 infants before the first dose of polio vaccine, 28&#xa0;days after completing primary polio immunization, and at 24&#xa0;months old. Infants were classified into six polio immunization program groups: 1sIPV+2bOPV, 2sIPV+1bOPV, 2sIPV+1tOPV, 1cIPV+2bOPV, 2cIPV+1bOPV, and 2cIPV+1tOPV (sIPV: Sabin inactivated poliovirus vaccine; cIPV: Salk inactivated poliovirus vaccine; b, bivalent; t, trivalent; OPV, oral polio vaccine). No significant differences existed in antibody titers against HepA virus (anti-HAV) among the polio immunization program groups at any of the three time points (pre-first dose [<i>p</i> =&#xa0;0.412], 28&#xa0;days after primary immunization [<i>p</i> =&#xa0;0.676], 24&#xa0;months old [<i>p</i> =&#xa0;0.556]). Before the first dose (<i>p</i> =&#xa0;0.178) and at age 24&#xa0;months (<i>p</i> =&#xa0;0.987), no significant differences existed in HepB surface antibody (HBsAb) titers between the six polio immunization program groups). Twenty-eight days after primary immunization, no significant difference existed in HBsAb titers between groups after Bonferroni correction. Following HepA and HepB immunization, anti-HAV and HBsAb positivity reached &gt; 98% in all groups, reflecting effective immunization. Our data suggest that different polio immunization programs did not affect HepA and HepB vaccine efficacy; HepA and HepB vaccines maintained high effectiveness irrespective of polio immunization program. This trial was registered on Clinical Trials.gov: NCT03614702.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shiyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yuping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhiyao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Faculty of Science, The University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Hongyuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guoliang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianfeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of respiratory virus vaccine, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Zhifang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory of respiratory virus vaccine, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jingsi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03614702</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035922">Hepatitis A Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006510">Hepatitis B Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006506" MajorTopicYN="Y">Hepatitis A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035922" MajorTopicYN="N">Hepatitis A Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="Y">Hepatitis B</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006510" MajorTopicYN="N">Hepatitis B Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inactivated poliovirus vaccines</Keyword><Keyword MajorTopicYN="N">hepatitis A virus</Keyword><Keyword MajorTopicYN="N">hepatitis B virus</Keyword><Keyword MajorTopicYN="N">oral poliovirus vaccines</Keyword><Keyword MajorTopicYN="N">sequential vaccination program</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>19</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35044877</ArticleId><ArticleId IdType="pmc">PMC8993082</ArticleId><ArticleId IdType="doi">10.1080/21645515.2021.2024063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bandyopadhyay AS, Garon J, Seib K, Orenstein WA.. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791&#x2013;6. PMID: 25824845. doi:10.2217/fmb.15.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.15.19</ArticleId><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative . Two out of three wild poliovirus strains eradicated. Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland. 2019</Citation></Reference><Reference><Citation>Ghendon Y, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ. 1994;72:973&#x2013;83. PMID: 7867144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2486742</ArticleId><ArticleId IdType="pubmed">7867144</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M, Zipursky S, Orenstein W, Garon J, Zaffran M. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14:749&#x2013;62. PMID: 25597843. doi:10.1586/14760584.2015.1001750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2015.1001750</ArticleId><ArticleId IdType="pubmed">25597843</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris J, Hyde T, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:934&#x2013;38. PMID: 27606675. doi:10.15585/mmwr.mm6535a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6535a3</ArticleId><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Meeting of the strategic advisory group of experts on immunization, November 2012 &#x2013; conclusions and recommendations. Wkly Epidemiol Rec. 2013; 88:1&#x2013;16. PMID: 23311010.</Citation><ArticleIdList><ArticleId IdType="pubmed">23311010</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses. Addendum to the Recommendations for the production and quality control of poliomyelitis vaccine (inactivated) WHO Technical Report Series, 2004, Annex. 2003.</Citation></Reference><Reference><Citation>China; NHaFPCotPsRo . Immunization schedules and instructions for vaccines of the national immunization program(2016 Version). Chin J Viral Dis. 2017;7(2):81&#x2013;86. PMID: 27279955. doi:10.11604/pamj.2016.23.128.8756.</Citation><ArticleIdList><ArticleId IdType="doi">10.11604/pamj.2016.23.128.8756</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Wang X, Ma F, Kang G, Ding Z, Ye C, Pan Y, Zhao Y, Hong S, Chen J, et al. Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis a vaccines: a report on additional observations from a phase IV study. Clin Microbiol Infect. 2019;25:1422&#x2013;27. PMID: 30496870. doi:10.1016/j.cmi.2018.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2018.11.005</ArticleId><ArticleId IdType="pubmed">30496870</ArticleId></ArticleIdList></Reference><Reference><Citation>Fangcheng Z, Xuanyi W, Mingding C, Liming J, Jie W, Qi J, Yuanping G, Wen Q, Yajuan X, Jiangsen M, et al. Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China. Hepat Mon. 2012;12:100&#x2013;05. PMID: 22509186. doi:10.5812/hepatmon.838.</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/hepatmon.838</ArticleId><ArticleId IdType="pmc">PMC3321316</ArticleId><ArticleId IdType="pubmed">22509186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, An J, Tu A, Liang X, Cui F, Zheng H, Tang Y, Liu J, Wang X, Zhang N, et al. Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. Hum Vaccin Immunother. 2016;12:2322&#x2013;26. PMID: 27494260. doi:10.1080/21645515.2015.1134069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1134069</ArticleId><ArticleId IdType="pmc">PMC5027719</ArticleId><ArticleId IdType="pubmed">27494260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhave S, Sapru A, Bavdekar A, Kapatkar V, Mane A. Long-term immunogenicity of single dose of live attenuated hepatitis A vaccine in Indian children. Indian Pediatr. 2015;52:687&#x2013;90. PMID: 26388627. doi:10.1007/s13312-015-0697-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13312-015-0697-8</ArticleId><ArticleId IdType="pubmed">26388627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemon SM. Immunologic approaches to assessing the response to inactivated hepatitis A vaccine. J Hepatol. 1993;18(Suppl 2):S15&#x2013;S19. PMID: 8182266. doi:10.1016/s0168-8278(05)80372-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0168-8278(05)80372-1</ArticleId><ArticleId IdType="pubmed">8182266</ArticleId></ArticleIdList></Reference><Reference><Citation>Song YJ, Lim J, Park WS, Sohn H, Lee MS, Shin DH, Kim CB, Kim H, Oh GJ, Ki M. Seropositivity among Korean Young Adults Approximately 2 years after a single-dose vaccination against Hepatitis A virus. PLoS One. 2015;10:e0142297. PMID: 26540392. doi:10.1371/journal.pone.0142297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0142297</ArticleId><ArticleId IdType="pmc">PMC4634992</ArticleId><ArticleId IdType="pubmed">26540392</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Zhang ZJZ, Pan JB, Zhang HR, Li RQ, Li MZ, Lu L, Huang F, Wu J. Surveillance of immunization effectiveness and titer of type I and type III polio vaccine in Beijing before and after the adjustment of immunization strategy in 2012-2018. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54:779&#x2013;83. doi:10.3760/cma.j.cn112150-20190621-00499.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112150-20190621-00499</ArticleId><ArticleId IdType="pubmed">32842302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciapponi A, Bardach A, Rey Ares L, Glujovsky D, Cafferata ML, Cesaroni S, Bhatti A. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database Syst Rev. 2019;12:Cd011260. PMID: 31801180. doi:10.1002/14651858.CD011260.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011260.pub2</ArticleId><ArticleId IdType="pmc">PMC6953375</ArticleId><ArticleId IdType="pubmed">31801180</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015;15:1273&#x2013;82. PMID: 26318714. doi:10.1016/S1473-3099(15)00219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00219-4</ArticleId><ArticleId IdType="pubmed">26318714</ArticleId></ArticleIdList></Reference><Reference><Citation>Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, Melar M, Gaensbauer JT, Weldon WC, Oberste MS, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158&#x2013;69. PMID: 27212429. doi:10.1016/S0140-6736(16)00703-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00703-0</ArticleId><ArticleId IdType="pubmed">27212429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G, Yin W, Cao Y, Tan L, Wu S, Cao Y, Fu X, Yan J, Jiang X. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: a systematic review and meta-analysis. Hum Vaccin Immunother. 2018;14:2636&#x2013;43. PMID: 29985751. doi:10.1080/21645515.2018.1489188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1489188</ArticleId><ArticleId IdType="pmc">PMC6314415</ArticleId><ArticleId IdType="pubmed">29985751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanra G, Yal&#xe7;in SS, Ceyhan M, Yurdak&#xf6;k K. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk J Pediatr. 2000;42:105&#x2013;08. PMID: 10936974.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936974</ArticleId></ArticleIdList></Reference><Reference><Citation>Linder N, Karetnyi Y, Gidony Y, Ohel G, Levin E, Kuint J, Davidovich N, Gidony I, Mendelson E, Barzilai A. Placental transfer of hepatitis A antibodies in full term and preterm infants. Pediatr Infect Dis J. 1997;16:245&#x2013;47. PMID: 9041609. doi:10.1097/00006454-199702000-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-199702000-00015</ArticleId><ArticleId IdType="pubmed">9041609</ArticleId></ArticleIdList></Reference><Reference><Citation>Linder N, Karetnyi Y, Gidony Y, Dagan R, Ohel G, Levin E, Mendelson E, Brazilai A. Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Infection. 1999;27:128&#x2013;31. PMID: 10219645. doi:10.1007/BF02560513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02560513</ArticleId><ArticleId IdType="pubmed">10219645</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez EL, Contrini MM, Xifr&#xf3; MC, Cattaneo MA, Zambrano B, Dumas R, Rouyrre N, Weber F. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules. Vaccine. 2007;25:102&#x2013;08. PMID: 16914234. doi:10.1016/j.vaccine.2006.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.07.014</ArticleId><ArticleId IdType="pubmed">16914234</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu XE, Wushouer F, Gou A, Kuerban M, Li X, Sun Y, Zhang J, Liu Y, J LI, Zhuang H. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China. Hum Vaccin Immunother. 2013;9:1460&#x2013;65. PMID: 23571173. doi:10.4161/hv.24366.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24366</ArticleId><ArticleId IdType="pubmed">23571173</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Zhang S, Luo C, Wu Q, Liu Q, Zhou YH, Hu Y. Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine. PLoS One. 2011;6:e25130. PMID: 21966434. doi:10.1371/journal.pone.0025130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025130</ArticleId><ArticleId IdType="pmc">PMC3178586</ArticleId><ArticleId IdType="pubmed">21966434</ArticleId></ArticleIdList></Reference><Reference><Citation>Roznovsky L, Orsagova I, Kloudova A, Tvrdik J, Kabieszova L, Lochman I, Mrazek J, Hozakova L, Zjevikova A, Pliskova L. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection. 2010;38:395&#x2013;400. PMID: 20589522. doi:10.1007/s15010-010-0039-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-010-0039-7</ArticleId><ArticleId IdType="pubmed">20589522</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan PK, Ngai KL, Lao TT, Wong MC, Cheung T, Yeung AC, Chan MC, Luk SW. Response to booster doses of hepatitis B vaccine among young adults who had received neonatal vaccination. PLoS One. 2014;9:e107163. PMID: 25198289. doi:10.1371/journal.pone.0107163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0107163</ArticleId><ArticleId IdType="pmc">PMC4157863</ArticleId><ArticleId IdType="pubmed">25198289</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing W, Liu J, Liu M. Eliminating mother-to-child transmission of HBV: progress and challenges in China. Front Med. 2020;14:21&#x2013;29. PMID:31974872. doi:10.1007/s11684-020-0744-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-020-0744-2</ArticleId><ArticleId IdType="pubmed">31974872</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T, Mo Z, Ying Z, Huang T, Che Y, Li G, Yang X, Sun M, Jiang L, Shi L, et al. Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants. Ann Transl Med. 2021;9:253. PMID: 33708880. doi10.21037/atm-20-2537.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-2537</ArticleId><ArticleId IdType="pmc">PMC7940937</ArticleId><ArticleId IdType="pubmed">33708880</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>